Skip to main content
PCSA
NASDAQ Life Sciences

Processa Letter Puts As-Converted Share Count at 309.3M vs 2.8M Trading

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.85
Mkt Cap
$5.415M
52W Low
$1.041
52W High
$9.303
52W Position info
78% above low
Off High info
80% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

PCSA sits 78% above its 52-week low of $1.041 on light trading volume (0.3× avg).

Summary

Processa's stockholder letter recaps the Vidya deal and IND clearance but newly quantifies the capital structure: 2.8 million common shares trading against 306.5 million Series A preferred shares as-converted, pending a second special meeting vote. It also states the July financing netted about $183.3 million and funds operations into the second half of 2029.


Key Events · Corporate Governance and Compliance · PCSA

  • As-Converted Share Count Disclosed

    The letter states 2.8 million common shares are currently outstanding versus 306.5 million Series A preferred shares as-converted, for approximately 309.3 million total common shares as-converted.

  • Conversion Needs a Second Vote

    Conversion of the Series A non-voting preferred into common requires stockholder approval at a second special meeting; definitive proxy materials for that meeting are still forthcoming, separate from the October 22, 2026 reverse-split proxy.

  • Net Proceeds and Runway Stated

    The July financing generated approximately $183.3 million in net proceeds and is expected to fund operations into the second half of 2029, covering the Phase 2 proof-of-concept plan in food allergy, CSU and relapsing MS.

  • Reverse Split Still Pending

    A separate special meeting will vote on a reverse stock split to maintain Nasdaq listing compliance, per the definitive proxy filed October 22, 2026.


Analysis · PCSA · Life Sciences

The letter is mostly a recap of the July Vidya deal, the October proxy filings and the October 29 IND clearance. What is new is the capitalization math: only about 2.8 million common shares trade today, while roughly 306.5 million more sit in Series A preferred that converts to common if stockholders approve. That approval is the subject of a second special meeting whose definitive proxy has not yet been filed, so the overhang is real but not yet tradable. The letter also puts the July raise at about $183.3 million in net proceeds with runway into the second half of 2029, which is the first hard funding figure tied to the Phase 2 plan. Investors holding the 2.8 million trading shares face the prospect of their stake being diluted roughly 110-fold on an as-converted basis if conversion is approved.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCSA was trading at $1.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $1.04 to $9.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCSA - Latest Insights

PCSA
Nov 13, 2026, 5:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $1.69 info
Change: -$0.170 (-9%) info
Market Cap: $4.729M info
PCSA
Oct 29, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.69 info
Change: -$0.260 (-13%) info
Market Cap: $4.729M info
PCSA
Oct 29, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.89
Real-time Price: $1.69 info
Change: -$0.200 (-11%) info
Market Cap: $4.729M info
PCSA
Oct 09, 2026, 4:03 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.69 info
Change: +$0.220 (+15%) info
Market Cap: $4.729M info
PCSA
Oct 09, 2026, 4:02 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.69 info
Change: +$0.220 (+15%) info
Market Cap: $4.729M info